enGene CMO Dr. Raj Pruthi resigns; effective June 16, 2025

enGene Therapeutics Inc.

Dr. Raj Pruthi resigned as Chief Medical Officer; resignation date June 3, 2025.
He will support orderly transition of responsibilities before leaving on June 16, 2025.
No successor named; responsibilities reallocated to other urology and clinical experts.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Dr. Raj S. Pruthi

Chief Medical Officer

ENGN · enGene Therapeutics Inc.

Effective: 2025-06-16
Filed: June 4, 2025, 7:59 PM ET

On June 3, 2025, Dr. Raj S. Pruthi notified enGene Holdings Inc. (the “Company”) of his resignation from his position as Chief Medical Officer of the Company, with his resignation to be effective as of close of business on June 16, 2025.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Dr. Raj S. Pruthi resigned as Chief Medical Officer at enGene Therapeutics Inc..

Action: resigned
Role: Chief Medical Officer

Exact text from the filing

On June 3, 2025, Dr. Raj S. Pruthi notified enGene Holdings Inc. (the “Company”) of his resignation from his position as Chief Medical Officer of the Company, with his resignation to be effective as of close of business on June 16, 2025.

View on SEC.gov

enGene Therapeutics Inc. filing history →

Source: SEC EDGAR

accession 0000929638-25-002133

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.